Search

everythinglearnresearchcommunity

for

Search:↓

A person experiencing hair loss is using finasteride and considering minoxidil but is worried about side effects like heart palpitations. They seek advice on continuing minoxidil, trying alternatives like microneedling, or considering a hair transplant.

A user shared their experience with hair loss treatments, including finasteride, minoxidil, and RU58841, which improved their hair from a diffuse NW3 to a solid NW2 - 2.5. They noticed significant changes in how people treated them after regrowing their hair, suggesting that attractiveness can greatly impact social interactions and opportunities.

User shared hair loss progress using 0.5 oral fin daily, 1ml liquid minox daily, Vitamin D, Biotin, and micro-needling. Regrowth improved from year 2 to year 3, showing medication needs time for full benefit.

User discusses Pyrilutamide's effectiveness for hair loss, needing more time for results. Others suggest waiting 6-12 months and ask about side effects.

A user shared their 10-year hair loss journey, detailing treatments including minoxidil (Kirkland and Alopexy 5%), finasteride, and recently starting dutasteride. They experienced varying results, with significant improvement from minoxidil and finasteride, and are currently seeing positive effects from dutasteride without side effects.

A 19-year-old experiencing mild hair loss plans to start finasteride and use Nizoral, avoiding minoxidil for now. Others share their experiences with finasteride, noting minimal side effects and advising against worrying about potential negative effects.

Finasteride is a controversial hair loss treatment, with some users experiencing positive results and others facing side effects like erectile dysfunction. The discussion emphasizes the importance of personal choice and informed decision-making.

The conversation is about microneedling for hair loss. The conclusion is that there are differing opinions on the depth and frequency of microneedling, with some studies suggesting positive results with 1.5mm depth once a week, while others prefer lower depths and less frequent sessions.

Norwood 1-3 hair loss is considered normal in Russia and not balding. Using finasteride for Norwood 1-3 is seen as unnecessary and risky.

A 21-year-old's hair loss worsened despite using finasteride, oral and topical minoxidil, microneedling, and keto shampoo for a year. They are considering switching to dutasteride and improving their diet.

RU58841 is effective for long-term hair loss treatment, often used with finasteride or dutasteride for better results. Users report varying experiences with side effects and effectiveness, with some noting improvements and others experiencing shedding or needing to adjust dosages.

A 43-year-old experienced hair loss and used Finasteride successfully for 18 years before switching to Dutasteride due to renewed thinning. After 6 months on Dutasteride, they experienced itching and increased hair loss, leading to concerns about prolonged shedding and considering switching back to Finasteride.

An 18-year-old experiencing aggressive hair loss has been using 1mg finasteride and 2.5mg oral minoxidil for 162 days but continues to shed hair. Suggestions include switching to dutasteride, considering topical minoxidil, and consulting a dermatologist for further evaluation.

Doctors recommend starting with minoxidil for hair loss due to its lower risk of side effects compared to finasteride. Some believe finasteride should be used early to address the root cause, but a conservative approach is preferred by medical professionals.

A young person regrets not starting hair loss treatments like minoxidil and finasteride earlier, leading to significant balding by age 19. They discuss the importance of early intervention and the impact of societal perceptions on those experiencing hair loss.

The conversation discusses alternatives for hair loss treatment for someone allergic to finasteride, suggesting options like hair systems, topical anti-androgens such as CB-03-01, RU58841, and kx-826. It highlights the challenges faced by individuals allergic to anti-androgen inhibitors and the need for more information on this topic.

A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

There is no imminent cure for hair loss, but treatments like Minoxidil, Finasteride, and new drugs such as KX-826, GT-20029, and PP405 are being explored. Current solutions focus on slowing hair loss and stimulating growth, with hopes for better options in the future.

PP405 is being discussed as a potential hair loss treatment, possibly more effective than minoxidil. There are concerns about its effectiveness and product contamination, but some users report early signs of hair regrowth.

The user is experiencing worsening hair loss despite using oral finasteride, oral minoxidil, microneedling, keto shampoo, and supplements for seven months. They are concerned about continued shedding and lack of regrowth, and are considering adding topical minoxidil to their routine.

The user is experiencing worsening hair loss despite using finasteride and is advised to add minoxidil to their treatment. Concerns about side effects and the effectiveness of combining finasteride and minoxidil are discussed.

The user is dealing with early hair loss and is using a serum with Redensyl, multivitamins, and plans to add minoxidil. They seek advice on maintaining a positive mindset and improving hair health through lifestyle changes.

Pelage Pharmaceuticals received $120 million in Series B funding for hair loss treatment development. The conversation expresses excitement and anticipation for the release and effectiveness of the treatment.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.

Minoxidil can stimulate hair growth but does not prevent long-term hair loss, while finasteride or dutasteride is necessary to address DHT and maintain hair. Family hair history may not predict individual outcomes, and combining treatments like microneedling can enhance results.

Dutasteride is effective for many in reducing hair loss and promoting regrowth, often with fewer side effects than finasteride. Combining it with minoxidil is commonly seen as a successful strategy, though results may take several months.

The user experienced no improvement in hair loss after using a dermatologist's minoxidil 10% and finasteride 0.1% solution, clotrimazole, daily dermarolling, and multivitamins. They plan to switch to oral finasteride and reduce dermarolling to once a week.

PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.

PP405, a promising hair loss treatment, is expected to be available by 2027, with faster trials due to its topical nature. Users are eager for its release, comparing it to existing treatments like minoxidil and finasteride, but remain cautious about its long-term effectiveness.